The CMS appeals committee ruled Medihelp can deny Elaprase therapy for a young Hunter syndrome patient, citing solvency over PMB obligations.
Medihelp denies funding for child with Hunter Syndrome
Original Article by Amanda Visser | Moneyweb | 4 July 2025
The CMS appeals committee ruled Medihelp can deny Elaprase therapy for a young Hunter syndrome patient, citing solvency over PMB obligations.
More Posts
Compounded semaglutide appeal dismissed
A court has upheld restrictions on compounded semaglutide at iDexis while regulatory investigations continue.
Read more...
WHO’s Africa Chief Urges Action, Not Talk, on Primary Healthcare
WHO Africa director Mohamed Janabi urged governments to finance primary healthcare and pursue health sovereignty.
Read more...
Unpaid specialist training strains SA doctors
Unpaid specialist training is growing in South Africa as scarce funded posts leave doctors working without salaries.
Read more...